BNP Paribas Financial Markets
VBIV

BNP Paribas Financial Markets’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

BNP Paribas Financial Markets’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,505
Closed -$17.7K – 4082
2022
Q4 		$17.7K Sell
1,505
-1,565
-51% -$27.6K ﹤0.01% 3559
2022
Q3 		$65K Buy
3,070
+1,481
+93% +$39.9K ﹤0.01% 3917
2022
Q2 		$38.5K Buy
1,589
+1,074
+209% +$36.5K ﹤0.01% 3612
2022
Q1 		$25.6K Sell
515
-791
-61% -$39.1K ﹤0.01% 3690
2021
Q4 		$91.7K Buy
1,306
+191
+17% +$16.1K ﹤0.01% 3620
2021
Q3 		$104K Buy
1,115
+796
+250% +$75.6K ﹤0.01% 3263
2021
Q2 		$32K Sell
319
-701
-69% -$68.3K ﹤0.01% 3408
2021
Q1 		$95.2K Buy
1,020
+248
+32% +$25.1K ﹤0.01% 3381
2020
Q4 		$63.7K Sell
772
-764
-50% -$65.2K ﹤0.01% 3441
2020
Q3 		$132K Buy
1,536
+1,109
+260% +$129K ﹤0.01% 2969
2020
Q2 		$39.7K Sell
427
-1,151
-73% -$63.4K ﹤0.01% 3143
2020
Q1 		$45K Buy
1,578
+600
+61% +$23.3K ﹤0.01% 3591
2019
Q4 		$40.5K Buy
978
+853
+682% +$18.7K ﹤0.01% 3753
2019
Q3 		$1.77K Buy
125
+101
+421% +$2.12K ﹤0.01% 4378
2019
Q2 		$856 Buy
24
+9
+60% +$488 ﹤0.01% 4377
2019
Q1 		$866 Hold
15
– – ﹤0.01% 4157
2018
Q4 		$741 Buy
15
+2
+15% +$110 ﹤0.01% 3960
2018
Q3 		$920 Hold
13
– – ﹤0.01% 4322
2018
Q2 		$1.04K Sell
13
-215
-94% -$20.8K ﹤0.01% 4296
2018
Q1 		$23.9K Sell
228
-9
-4% -$1.07K ﹤0.01% 3881
2017
Q4 		$30.4K Buy
237
+166
+234% +$20.4K ﹤0.01% 3876
2017
Q3 		$8.15K Sell
71
-5
-7% -$601 ﹤0.01% 3920
2017
Q2 		$9.89K Buy
+76
New +$10.3K ﹤0.01% 3947

Other funds holding VBIV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BNP Paribas Financial Markets's VBIV Position: Q1 2023 in Review

BNP Paribas Financial Markets sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q1 2023, closing a stake of 1,505 shares — an estimated $17.7K sold.

BNP Paribas Financial Markets first reported a position in VBIV in Q2 2017 and held it in 23 quarters. The position peaked at $132K in Q3 2020. 95 funds tracked by Wall St. Rank hold VBIV as of Q1 2023.

  • BNP Paribas Financial Markets reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q1 2023 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 1,505 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q1 2023, an estimated $17.7K.
  • BNP Paribas Financial Markets first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2017 and held it in 23 quarters.
  • BNP Paribas Financial Markets's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $132K in Q3 2020.
  • 95 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q1 2023.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2023, filed 12 May 2023.